(no title)
sdbrown | 2 years ago
If you want to get more reasonably unhappy with market exclusivity, look at Celgene's grip on thalidomide/lenalidomide/pomalidomide for the treatment of multiple myeloma.
sdbrown | 2 years ago
If you want to get more reasonably unhappy with market exclusivity, look at Celgene's grip on thalidomide/lenalidomide/pomalidomide for the treatment of multiple myeloma.
No comments yet.